2023-09-28T20:22:06-05:00 2022-12-31 953001179 WINDES INC PO BOX 87 LONG BEACH CA 90801 990 2022-01-01 953772528 PEDIATRIC CANCER RESEARCH FOUNDATION PEDI 9498596312 2151 MICHELSON DRIVE 180 IRVINE CA 92612 THOMAS BRENNAN TREASURER 9498596312 2023-09-14 1 THOMAS BRENNAN 999009999 1 DONITA JOSEPH P00286656 5624351191 2023-09-14 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z STEVE GUISTO 2151 MICHELSON DRIVE 180 IRVINE CA 92612 4526325 0 X WWW.PCRF-KIDS.ORG X 1982 CA THE FOUNDATION'S MISSION IS TO IMPROVE THE CARE, QUALITY OF LIFE AND SURVIVAL RATE OF CHILDREN WITH MALIGNANT DISEASES. THE FOUNDATION RAISES FUNDS TO SUPPORT STATE-OF-THE-ART RESEARCH THAT WILL ULTIMATELY LEAD TO A CURE FOR ALL CHILDHOOD CANCERS. 19 19 8 100 0 0 3381857 3808467 0 371375 66 10776 -559967 -1072633 2821956 3117985 2078326 2568802 0 0 491272 552779 0 0 756531 496523 1066087 3066121 4187668 -244165 -1069683 3627407 3281205 1093372 1816853 2534035 1464352 THE FOUNDATION'S MISSION IS TO IMPROVE THE CARE, QUALITY OF LIFE AND SURVIVAL RATE OF CHILDREN WITH MALIGNANT DISEASES. THE FOUNDATION RAISES FUNDS TO SUPPORT STATE-OF-THE-ART RESEARCH THAT WILL ULTIMATELY LEAD TO A CURE FOR ALL CHILDHOOD CANCERS. 0 0 3294094 2568802 371375 PEDIATRIC CANCER RESEARCH ACTIVITIES - PRIMARY FUNDING SOURCE FOR RESEARCH STUDIES, STAFF & EQUIPMENT NEEDS FOR PEDIATRIC CANCER RESEARCH LABS. SEE SCHEDULE I FOR ADDITIONAL DETAIL. 3294094 1 1 0 0 0 0 0 0 0 0 1 0 1 1 1 1 1 0 0 0 1 1 0 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 7 0 1 8 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 19 19 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA NY IL NJ X X JERI WILSON 9498596312 2151 MICHELSON DRIVE 180 IRVINE CA 92612 STEVE GIUSTO PRESIDENT 1.00 X X 0 0 0 JOHN WEINER VICE PRESIDENT 1.00 X X 0 0 0 THOMAS BRENNAN TREASURER 1.00 X X 0 0 0 KEITH KOELLER SECRETARY 1.00 X X 0 0 0 ELIZABETH MCNULTY DIRECTOR 1.00 X 0 0 0 JOHN COON DIRECTOR 1.00 X 0 0 0 CHERIE DALY DIRECTOR 1.00 X 0 0 0 JOHN S VALLELY DIRECTOR 1.00 X 0 0 0 SCOTT A ECKER DIRECTOR 1.00 X 0 0 0 SUSIE BUCHAN DIRECTOR 1.00 X 0 0 0 TIM CROMWELL DIRECTOR 1.00 X 0 0 0 JANET MITCHELL DIRECTOR 1.00 X 0 0 0 CAMERON MUNSON DIRECTOR 1.00 X 0 0 0 BETH ABRAMS DIRECTOR 1.00 X 0 0 0 LEN SHULMAN DIRECTOR 1.00 X 0 0 0 BRAD NEGLIA DIRECTOR 1.00 X 0 0 0 TROY A VARENCHIK DIRECTOR 1.00 X 0 0 0 JERI WILSON EXECUTIVE DIRECTOR 40.00 X X 204615 0 16700 AMANDA SARATISIS MD DIRECTOR 1.00 X 0 0 0 DARTH VAUGHN DIRECTOR 1.00 X 0 0 0 204615 0 16700 1 0 1 0 RED FOX COMMUNICATIONS 67 FOREST ROAD TENAFLY NJ 07670 MARKETING SERVICES 130000 1 X 2002318 82933 1723216 492888 3808467 INTERNATIONAL SYMPOSIUM 900099 371375 371375 371375 10776 10776 283001 2002318 1408340 -1125339 -1125339 52706 0 52706 52706 3117985 371375 0 -1061857 2455802 2455802 88000 88000 25000 25000 221314 80096 25362 115856 286962 103855 32885 150222 8874 3212 1017 4645 35629 12895 4083 18651 5921 830 788 4303 77869 10922 10361 56586 208972 79889 20078 109005 137192 137192 11250 1578 1497 8175 146676 53303 16575 76798 319060 319060 558 333 56 169 12552 919 6643 4990 OTHER PROGRAM SERVICES 51073 51073 POSTAGE, PRINTING, AND 41911 4356 6534 31021 MISCELLANEOUS 40333 2971 10206 27156 CREDIT CARD FEES 12720 958 11762 4187668 3294094 137043 756531 1976086 1126434 1149589 222357 161432 153450 85365 181147 61415 61415 558 0 987450 250000 250000 4377 360367 3627407 3281205 68072 183556 895784 1068726 46583 186355 82933 378216 1093372 1816853 X 2534035 1464352 2534035 1464352 3627407 3281205 -1069683 0 X 0 1 X 1 0 X 2581334 2746067 3436116 3381857 3808467 15953841 2581334 2746067 3436116 3381857 3808467 15953841 317482 15636359 13893 18443 8518 66 10776 51696 153991 202669 48753 52706 458119 16463656 648716 0.94980 0.93120 X 0.93120 0.00300 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 3064 3064 0 12566 12566 0 45785 45785 0 0 INVESTMENT IN ONCOHEROES BIOSCIENCES, INC. 250000 C 250000 DEPOSITS 7570 OPERATING LEASE RIGHT-OF-USE ASSET 352797 360367 OPERATING LEASE LIABILITY 378216 378216 X 3117985 0 3117985 0 3117985 4187668 0 4187668 0 4187668 PART X, LINE 2: FIN 48: FASB ASC TOPIC 740, INCOME TAXES, REQUIRES MANAGEMENT TO EVALUATE THE TAX POSITIONS TAKEN BY THE FOUNDATION AND TO RECOGNIZE A TAX LIABILITY IF THE FOUNDATION HAS TAKEN AN UNCERTAIN POSITION THAT MORE LIKELY THAN NOT WOULD NOT BE SUSTAINED UPON EXAMINATION BY THE INTERNAL REVENUE SERVICE. MANAGEMENT HAS ANALYZED THE TAX POSITIONS TAKEN BY THE FOUNDATION AND HAS CONCLUDED THAT, AS OF DECEMBER 31, 2022, THERE ARE NO UNCERTAIN POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, THAT WOULD REQUIRE RECOGNITION OF A LIABILITY OR DISCLOSURE IN THE FINANCIAL STATEMENTS. THE FOUNDATION IS SUBJECT TO ROUTINE AUDITS BY THE TAXING JURISDICTIONS. THE STATUTE OF LIMITATIONS FOR FEDERAL AND CALIFORNIA PURPOSES IS GENERALLY THREE AND FOUR YEARS, RESPECTIVELY. FORM 990, PART X, LINE 13: PROGRAM-RELATED INVESTMENTS DURING THE YEAR ENDED DECEMBER 31, 2021, THE FOUNDATION INVESTED $250,000 IN A SIMPLE AGREEMENT FOR FUTURE EQUITY (SAFE) WITH ONCOHEROES BIOSCIENCES INC. (ONCOHEROES). THE SAFE INVESTMENT GIVES PCRF THE RIGHT TO CERTAIN SHARES OF ONCOHEROES CAPITAL STOCK, WHICH IS CARRIED AT COST. THE RIGHT TO THE SHARES IS AVAILABLE TO THE FOUNDATION UPON A CHANGE IN CONTROL OR INITIAL PUBLIC OFFERING BY ONCOHEROES, EITHER DEFINED AS A LIQUIDITY EVENT IN THE AGREEMENT. IF THERE IS A LIQUIDITY EVENT, AND THE RIGHT TO RECEIVE ONCOHEROES SHARES IS NOT EXERCISED BY THE FOUNDATION, THE FOUNDATION WILL RECEIVE A CASH PAYMENT OF 200% OF THE INVESTMENT AMOUNT. THIS INVESTMENT HAS NOT BEEN EVALUATED FOR IMPAIRMENT BECAUSE IT IS NOT PRACTICABLE TO ESTIMATE THE FAIR VALUE DUE TO INSUFFICIENT INFORMATION BEING AVAILABLE AND MANAGEMENT HAS NOT IDENTIFIED ANY EVENTS OR CHANGES IN CIRCUMSTANCES THAT MIGHT HAVE A SIGNIFICANT ADVERSE EFFECT ON THE FAIR VALUE OF THE INVESTMENT. THE FAIR VALUE OF THIS INVESTMENT MAY DIFFER FROM THE AMOUNT RECORDED. 1 0 0 0 0 0 0 0 0 0 EUROPE (INCLUDING ICELAND & GREENLAND) PROGRAM SERVICE EXPENSE TO SUPPORT ORGANIZATIONS HELPING THE CHILDREN OF UKRAINE. 25000 WIRE 0 CASH 1 0 0 0 0 0 0 PART III ACCOUNTING METHOD: RUN/WALK 568873 568873 17508 4725 396723 BID FOR KIDS CA 516362 467762 48600 2613 53547 700 48710 15 1200084 965683 234401 175958 72310 1492 634054 2285319 2002318 283001 196079 130582 2192 1079487 1408340 -1125339 52706 0 52706 52706 CA NJ 1 0 0 0 1.00000 0 0 1 DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 75000 0 PROSPECTIVE VALIDATION OF A PROGNOSTIC LIQUID BIOPSY APPROACH FOR PEDIATRIC EWING SARCOMA CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH ST PHILADELPHIA PA 13146 231352166 501(C)(3) 125000 0 PRECISION MEDICINE TO EXPLOIT BCL2-FAMILY SURVIVAL DEPENDENCIES IN NEUROBLASTOMA SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 910564748 501(C)(3) 30000 0 DEVELOPMENT OF TUNABLE ON-OFF CAR T CELLS FOR SAFE AND DURABLE TUMOR CONTROL NEW YORK MEDICAL COLLEGE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595 131099420 501(C)(3) 900000 0 PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NYMC UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD UNIT 307 HOUSTON TX 77210 766001118 501(C)(3) 125000 0 COMBINING A NOVEL DENDRITIC CELL VACCINE WITH CHECKPOINT BLOCKADE FOR OSTEOSARCOMA THERAPY UNIVERSITY OF ALABAMA AT BIRMINGHAM 1600 7TH AVENUE SOUTH LOWDER 512 BIRMINGHAM AL 35233 636005396 501(C)(3) 75000 0 ENHANCEMENT OF IMMUNOVIROTHERAPY WITH DIRECTED DRUG DELIVERY FOR TREATMENT OF PEDIATRIC HIGH-GRADE GLIOMA BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA BCM 310 HOUSTON TX 77030 741613878 501(C)(3) 75000 0 OFF-THE-SHELF COMBINATION CANCER IMMUNOTHERAPY WITH ONCOLYTIC ADENO-IMMUNOTHERAPY AND CAR NK CELL THERAPY FOR PEDIATRIC SARCOMA ANN & ROBERT LURIE CHILDREN'S HOSPITAL 225 E CHICAGO AVE BOX 4 CHICAGO IL 60611 362170833 501(C)(3) 75000 0 INTRANASAL DELIVERY OF TARGETING NANOLIPOSOMAL THERAPEUTICS FOR PEDIATRIC GLIOMA MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02145 041564655 501(C)(3) 29700 0 OPTIMIZING CAR T CELL IMMUNOTHERAPY FOR PEDIATRIC RHABDOMYOSARCOMA ANN & ROBERT LURIE CHILDREN'S HOSPITAL 225 E CHICAGO AVE BOX 4 CHICAGO IL 60611 362170833 501(C)(3) 25000 0 IMMUNOTHERAPY FOR DIPG HOPE FOR HENRY FOUNDATION 2440 WISCONSIN AVE NW SUITE 201 WASHINGTON DC 20007 200244173 501(C)(3) 50000 0 REINVENTING HOW HOSPITALS CARE FOR SERIOUSLY ILL CHILDREN AND THEIR FAMILIES THROUGH INNOVATIVE PROGRAMS THAT ENTERTAIN, REDUCE STRESS, AND EMPOWER CHILDREN TO BE ACTIVE PARTICIPANTS IN THEIR OWN CARE. TEXAS CHILDREN'S HOSPITAL 6701 FANIN SUITE 151028 HOUSTON TX 77030 741100555 501(C)(3) 50000 0 DEVELOPING A SENSITIVE METHOD FOR CIC FUSION GENE DETECTION IN SARCOMAS BY CUSTOMIZED GENOMIC SEQUENCING STANFORD UNIVERSITY 3172 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 75000 0 DEVELOPMENT OF SMALL MOLECULES TO TARGET CRED:CBP INTERACTION FOR TREATMENT OF AML UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94118 946036493 501(C)(3) 115000 0 MODULATING THE IMMUNE MICROENVIRONMENT IN PEDIATRIC ACUTE MYELOID LEUKEMIA UCLA FOUNDATION 10889 WILSHIRE BLVD SUITE 150 LOS ANGELES CA 90027 952250801 501(C)(3) 55000 0 RESEARCH INTO MULTIDISCIPLINARY APPROACH TO SIGNIFICANTLY AND POSITIVELY IMPROVE THE QUALITY OF LIFE AND QUALITY OF CARE FOR CHILDREN AND YOUNG PEOPLE WITH CANCER LUCILLE PACKARD CHILDREN'S HOSPITAL 400 HAMILTON AVE SUITE 340 PALO ALTO CA 94301 770003859 501(C)(3) 50000 0 EFFECTIVE THERAPY FOR PEDIATRIC HIGH-GRADE GLIOMAS 16 0 SCHOLARSHIPS 69 88000 PART I, LINE 2: ACCORDING TO ITS ESTABLISHED GUIDELINES, PCRF SUPPORTS RESEARCH INTENDED TO DEVELOP INNOVATIVE APPROACHES TO THE TREATMENT, DIAGNOSIS AND PREVENTION OF PEDIATRIC CANCER. GRANTS ARE AWARDED TO PRINCIPAL INVESTIGATORS HOLDING AN MD OR PHD DEGREE WORKING IN DOMESTIC RESEARCH INSTITUTIONS. GRANTS ARE SUBJECT TO SCIENTIFIC PEER REVIEW BY AN INDEPENDENT COMMITTEE OF ONCOLOGISTS OR SCIENTISTS AND ARE ALSO SUBJECT TO BUDGETARY CONSTRAINTS AS DETERMINED BY PCRF'S BOARD OF DIRECTORS. REVIEW CRITERIA INCLUDES: 1) THE PROBABILITY OF AN ADVANCE IN PREVENTION, DIAGNOSIS OR TREATMENT FOR THE NEAR-TERM, 2) NOVELTY OF THE CONCEPT AND STRATEGY, 3) CLARITY OF PRESENTATION, 4) EXPERIENCE AND QUALIFICATIONS OF THE INVESTIGATORS, 5) ADEQUACY OF RESOURCES AND ENVIRONMENT, AND, 6) OVERALL PLAN FOR BRINGING THE RESEARCH FINDINGS TO CLINICAL APPLICATION. FUNDING REQUESTS MUST BE CONSISTENT WITH THE OBJECTIVES OF THE PROJECT AND GENERALLY NOT INCLUDE OVERHEAD OR INDIRECT COSTS. CERTAIN GRANT PAYMENTS ARE MADE ONLY AFTER SUBMISSION AND REVIEW OF QUARTERLY REPORTS. SUBMISSION OF SCIENTIFIC RESULTS AND UPDATES MUST BE MADE ANNUALLY. X 0 0 0 0 0 0 0 0 0 JERI WILSON EXECUTIVE DIRECTOR 194615 0 10000 0 0 0 10700 0 6000 0 221315 0 0 0 X 4 15336 FAIR MARKET VALUE X DONATED AUCTION ITEMS 283 477552 FAIR MARKET VALUE 0 1 0 PART I, COLUMN (B): THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION B, LINE 11B DESCRIBE THE PROCESS THE ORGANIZATION USES TO REVIEW FORM 990. THE FINAL VERSION OF THE FORM 990 IS PROVIDED TO THE FINANCE COMMITTEE AFTER THE DETAILED REVIEW IS COMPLETED BY THE FINANCIAL DIRECTOR AND THE TREASURER. THE TREASURER DISTRIBUTES A COPY OF THE FINAL VERSION OF THE FORM 990 TO THE BOARD OF DIRECTORS FOR FINAL REVIEW PRIOR TO FILING. THE RETURN IS FILED AFTER THE BOARD REVIEWS THE FORM 990. FORM 990, PART VI, SECTION B, LINE 12C DESCRIBE HOW THE ORGANIZATION MONITORS AND ENFORCES COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY. ALL BOARD MEMBERS, KEY EMPLOYEES, AND MANAGEMENT ARE COVERED BY THE CONFLICT OF INTEREST POLICY. DETERMINATIONS OF CONFLICT AND REVIEW OF CONFLICT IS PERFORMED AT THESE VARIOUS LEVELS OF THE ORGANIZATION. APPROPRIATE ACTION DEPENDING ON THE CONFLICT IS TAKEN BY MANAGEMENT, KEY EMPLOYEES AND THE BOARD. DISCLOSURE FORMS ARE REQUIRED ANNUALLY BY EACH MEMBER OF THE BOARD OF DIRECTORS, KEY EMPLOYEES, AND MANAGEMENT. FORM 990, PART VI, SECTION B, LINE 15 DESCRIBE THE PROCESS FOR DETERMINING COMPENSATION OF THE ORGANIZATIONS MANAGEMENT AND KEY EMPLOYEES. THE COMPENSATION COMMITTEE AND BOARD APPROVES COMPENSATION OF TOP MANAGEMENT. THE COMPENSATION COMMITTEE REVIEWED INDUSTRY STANDARD COMPENSATIONS. FORM 990, PART VI, SECTION C, LINE 19 DESCRIBE HOW THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. THE FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. THE CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART VIII, LINE 1E IN MARCH 2020, CONGRESS PASSED THE PAYCHECK PROTECTION PROGRAM (PPP) UNDER DIVISION A, TITLE I OF THE CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY ACT (CARES ACT), AUTHORIZING LOANS TO SMALL BUSINESSES FOR USE IN PAYING EMPLOYEES THAT THEY CONTINUE TO EMPLOY THROUGHOUT THE COVID-19 PANDEMIC AND FOR RENT, UTILITIES, AND INTEREST ON MORTGAGES. LOANS OBTAINED THROUGH THE PROGRAM ARE ELIGIBLE TO BE FORGIVEN AS LONG AS THE PROCEEDS ARE USED FOR QUALIFYING PURPOSES AND CERTAIN CONDITIONS ARE MET. IN FEBRUARY 2021, THE FOUNDATION RECEIVED A LOAN IN THE AMOUNT OF $82,933 THROUGH THE PPP. IN JULY 2022, THE FOUNDATION RECEIVED NOTIFICATION FROM THE SMALL BUSINESS ADMINISTRATION (SBA) THAT THE LOAN WAS FORGIVEN IN FULL. FOR THE YEAR ENDED DECEMBER 31, 2022, THE FOUNDATION RECOGNIZED INCOME FROM THE LOAN FORGIVENESS TOTALING $82,933 AND IS INCLUDED IN THE ACCOMPANYING STATEMENT OF ACTIVITIES AND CHAN PEDIATRIC CANCER RESEARCH FOUNDATION NEW YORK A NOT FOR PROFIT CORPORATION 17932 SKY PARK CIRCLE STE E IRVINE CA 92618 273051697 FUNDING SOURCE FOR RESEARCH NY 501(C)(3) LINE 4 N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0